Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate. 1994, 25: 249-265.
Article
CAS
PubMed
Google Scholar
Denmeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996, 28: 251-265. 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G.
Article
CAS
PubMed
Google Scholar
Miyamoto H, Messing EM, Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004, 61: 332-353. 10.1002/pros.20115.
Article
CAS
PubMed
Google Scholar
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002, 168: 429-435. 10.1097/00005392-200208000-00006.
Article
CAS
PubMed
Google Scholar
Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ, Koivisto PA: Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest. 2001, 81: 1647-1651.
Article
CAS
PubMed
Google Scholar
Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992, 41: 665-669. 10.1016/0960-0760(92)90401-4.
Article
CAS
PubMed
Google Scholar
Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H: Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999, 81: 242-251. 10.1038/sj.bjc.6690684.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mohr S, Leikauf GD, Keith G, Rihn BH: Microarrays as cancer keys: an array of possibilities. J Clin Oncol. 2002, 20: 3165-3175. 10.1200/JCO.2002.12.073.
Article
CAS
PubMed
Google Scholar
Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 2001, 61: 4683-4688.
CAS
PubMed
Google Scholar
Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HFJ, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61: 5974-5978.
CAS
PubMed
Google Scholar
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002, 419: 624-629. 10.1038/nature01075.
Article
CAS
PubMed
Google Scholar
Warburg O: On the origin of cancer cells. Science. 1956, 123: 309-314.
Article
CAS
PubMed
Google Scholar
Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P: Going malignant: the hypoxia-cancer connection in the prostate. Bioessays. 2002, 24: 749-757. 10.1002/bies.10131.
Article
CAS
PubMed
Google Scholar
Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A: Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology. 2002, 60: 634-639. 10.1016/S0090-4295(02)01858-7.
Article
PubMed
Google Scholar
Buttyan R, Ghafar MA, Shabsigh A: The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol. 2000, 10: 415-420. 10.1097/00042307-200009000-00009.
Article
CAS
PubMed
Google Scholar
Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK: Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Dis. 2002, 5: 236-245. 10.1038/sj.pcan.4500582.
Article
CAS
PubMed
Google Scholar
Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF: Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate. 2002, 50: 222-235. 10.1002/pros.10054.
Article
CAS
PubMed
Google Scholar
Rothermund CA, Gopalakrishnan VK, Vishwanatha JK: Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer. Prostate Cancer Prostatic Dis. 2004, 7: 158-164. 10.1038/sj.pcan.4500717.
Article
CAS
PubMed
Google Scholar
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiao SY, Wang HL, Hart J, Fleming D, Beard MR: cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol. 2001, 159: 1415-1421.
Article
CAS
PubMed
PubMed Central
Google Scholar
Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M: Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer. 2003, 106: 848-855. 10.1002/ijc.11313.
Article
CAS
PubMed
Google Scholar
Ito S, Nemoto T, Satoh S, Sekihara H, Seyama Y, Kubota S: Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophys. 2000, 373: 72-82. 10.1006/abbi.1999.1535.
Article
CAS
PubMed
Google Scholar
Nishimori I, FujikawaAdachi K, Onishi S, Hollingsworth MA: Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes. Ann N Y Acad Sci. 1999, 880: 5-16.
Article
CAS
PubMed
Google Scholar
Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, Jaklitsch MT, Sugarbaker DJ, Bueno R: Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003, 95: 598-605.
Article
CAS
PubMed
Google Scholar
Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995, 92: 5510-5514.
Article
CAS
PubMed
PubMed Central
Google Scholar
Semenza G: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002, 64: 993-998. 10.1016/S0006-2952(02)01168-1.
Article
CAS
PubMed
Google Scholar
Fang J, Yan L, Shing Y, Moses MA: HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. 2001, 61: 5731-5735.
CAS
PubMed
Google Scholar
Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001, 61: 6669-6673.
CAS
PubMed
Google Scholar
Bruick RK: Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A. 2000, 97: 9082-9087. 10.1073/pnas.97.16.9082.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL: Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A. 1989, 86: 297-301.
Article
CAS
PubMed
PubMed Central
Google Scholar
Albrecht M, Gillen S, Wilhelm B, Doroszewicz J, Aumuller G: Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol. 2002, 168: 336-342. 10.1097/00005392-200207000-00101.
Article
CAS
PubMed
Google Scholar
Usmani BA, Harden B, Maitland NJ, Turner AJ: Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond). 2002, 103 Suppl 48: 314S-317S.
Article
Google Scholar
Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM: Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res. 2001, 7: 1370-1377.
CAS
PubMed
Google Scholar
Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM: Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest. 2000, 106: 1399-1407.
Article
CAS
PubMed
PubMed Central
Google Scholar
Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998, 4: 50-57. 10.1038/nm0198-050.
Article
CAS
PubMed
Google Scholar
Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM: Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol. 2000, 170: 131-142. 10.1016/S0303-7207(00)00326-9.
Article
CAS
PubMed
Google Scholar
Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF: Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997, 272: 12650-12661. 10.1074/jbc.272.19.12650.
Article
CAS
PubMed
Google Scholar
Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF: Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem. 1996, 271: 6050-6061. 10.1074/jbc.271.11.6050.
Article
CAS
PubMed
Google Scholar
Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ: Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene. 2000, 19: 6297-6305. 10.1038/sj.onc.1204012.
Article
CAS
PubMed
Google Scholar
Chen G, Cizeau J, Vande VC, Park JH, Bozek G, Bolton J, Shi L, Dubik D, Greenberg A: Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem. 1999, 274: 7-10. 10.1074/jbc.274.1.7.
Article
CAS
PubMed
Google Scholar
Crow MT: Hypoxia, BNip3 proteins, and the mitochondrial death pathway in cardiomyocytes. Circ Res. 2002, 91: 183-185. 10.1161/01.RES.0000030195.38795.CF.
Article
CAS
PubMed
Google Scholar
Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA: Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A. 2002, 99: 12825-12830. 10.1073/pnas.202474099.
Article
CAS
PubMed
PubMed Central
Google Scholar
Regula KM, Ens K, Kirshenbaum LA: Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res. 2002, 91: 226-231. 10.1161/01.RES.0000029232.42227.16.
Article
CAS
PubMed
Google Scholar
Endo T, Kohda D: Functions of outer membrane receptors in mitochondrial protein import. Biochim Biophys Acta. 2002, 1592: 3-14. 10.1016/S0167-4889(02)00259-8.
Article
CAS
PubMed
Google Scholar
Lin Z, Weinberg JM, Malhotra R, Merritt SE, Holzman LB, Brosius FCIII: GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. Am J Physiol Endocrinol Metab. 2000, 278: E958-E966.
CAS
PubMed
Google Scholar
Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001, 158: 905-919.
Article
CAS
PubMed
PubMed Central
Google Scholar
Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP: Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002, 277: 26321-26326. 10.1074/jbc.M203310200.
Article
CAS
PubMed
Google Scholar